Mina S Farag, Margo J H van Campenhout, M J Sonneveld, Scott Fung, Karel J van Erpecum, David K Wong, Elke Verhey, Robert de Man, Robert J De Knegt, Johannes T Brouwer, Hubertus C Baak, Jordan J Feld, Kin Seng Liem, André Boonstra, Bettina E Hansen, Harry L A Janssen
We studied whether 48 weeks of PEG-IFN alfa-2a add-on increases HBsAg-decline and clearance in HBeAg-negative patients on long-term nucleo(s)tide analogue (NA) therapy. In this investigator-initiated, randomized, controlled trial conducted in Europe and Canada, HBeAg-negative patients treated with NA > 12 months, with HBVDNA < 200 IU/mL, were enrolled. Patients were randomized 2:1 to 48 weeks of PEG-IFN alfa-2a add-on (180 μg per week) or continued NA-monotherapy with subsequent follow-up to Week 72...
January 19, 2024: Journal of Viral Hepatitis